Statement from FDA Commissioner Scott Gottlieb, M.D. on advancing the development of novel treatments for neurological conditions; part of broader effort on modernizing FDA’s new drug review programs
FDA’s 5 guidance documents provide details for drug development for neurological conditions such as ALS and Alzheimer’s disease
